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Prospective determination of candidates for
thrombolysis in patients with acute proximal deep
vein thrombosis
Seth J. Klein, MD, Antonios P. Gasparis, MD, Dimitrios Virvilis, MD, John A. Ferretti, MD, and
Nicos Labropoulos, PhD, Stony Brook, NY
Purpose: To prospectively determine the distribution, extent, and age of venous thrombosis in patients presenting with
acute signs and symptoms of venous thromboembolism and identify candidates for thrombolysis.
Materials and Methods: Five hundred seventy-six consecutive patients (281 male, 295 female; mean age 58) referred for
lower extremity deep vein thrombosis (DVT) assessment between November 2007 and April 2008 were included in the
study. Documented cases of DVT were categorized by age (acute, chronic, and acute on chronic), anatomic location, and
extent. Patients with iliofemoral and femoropopliteal DVT were evaluated for thrombolysis using standard criteria.
Results:DVT was found in 19% of patients (112/576). Of these, 31 patients (27.7%, 31/112) had isolated calf DVT, 61
patients (54.5%, 61/112) had proximal vein thrombosis extending into the femoropopliteal venous segments, and 20
patients (17.9%, 20/112) presented with iliofemoral DVT. Using standard criteria, 12 patients were selected as potential
candidates for pharmacomechanical thrombolysis (PhMT). This equated to an incidence of 2% (12/576) in the
population studied, 11% of patients (12/112) with DVT, 26.1% of patients (12/46) presenting with acute proximal
DVT, and 20% of patients (4/20) with iliofemoral DVT.
Conclusion: The incidence of potential candidates for thrombolysis is low. These data should be considered when recruiting
centers to participate in ongoing clinical trials assessing the efficacy of these techniques. (J Vasc Surg 2010;51:908-12.)Deep vein thrombosis (DVT) is a significant cause of
morbidity and mortality with major physical and socioeco-
nomic sequelae for patients.1 Studies have shown that
iliofemoral thrombosis is associated with a higher incidence
of recurrent DVT and post-thrombotic syndrome.2-4 Ve-
nous claudication is almost exclusively present in patients
with iliofemoral DVT.2,5 So far, conventional treatment
has been limited to anticoagulation and compression ther-
apy alone. However, emerging data suggests that catheter-
directed thrombolysis (CDT), in combination with appro-
priate anticoagulation, improves outcome with regard to
recurrent DVT, venous obstruction, valve competence, and
quality of life.6-9 Venous thrombectomy and pharmacome-
chanical thrombolysis (PhMT) have also been used for
treating acute proximal thrombosis.10-12 Although recent
studies have shown favorable outcomes with CDT in the
treatment of acute DVT, no large randomized studies are
currently available to provide the needed evidence to sup-
port this treatment approach. Furthermore, the percentage
of patients with DVT that would be candidates for throm-
bolysis, based on currently acceptable indications, has not
been determined. This study was designed to determine the
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908incidence of DVT and the number of patients who would
be eligible for thrombolysis using standard criteria.
PATIENTS AND METHODS
This was a Health Insurance Portability and Account-
ability Act (HIPAA) compliant study that was approved by
our institutional review board. The patient’s informed con-
sent was waved. Consecutive patients between November
2007 and April 2008 that were referred to our university
hospital vascular lab to be evaluated for lower extremity
venous thrombosis were prospectively collected. Indica-
tions for assessing these patients were signs and symptoms
of venous thromboembolism and high-risk asymptomatic
patients, such as those that underwent total joint arthrop-
athy or complex neurosurgery procedures. Patients need-
ing evaluation of their upper extremity veins were not
included in the analysis. All patients were examined with
duplex ultrasound (DU) scan using a technique previously
described by our group.13 A form accompanying each exam
was completed to include demographic information, rele-
vant clinical data, and DU scan findings including the
extent, age, and distribution of the thrombus. Contraindi-
cations to thrombolysis were determined after DU scan
exam by a staff physician. All DU scans were performed in
an Intersocietal Commission for the Accreditation of Vas-
cular Laboratories (ICAVL) accredited laboratory by reg-
istered vascular technologists that had performed over
2000 tests for DVT before the initiation of the study. All
exams of the current study were interpreted by a single
experienced observer (N.L.).
The DU scan was performed in the supine position to
detect obstruction and in the standing position for reflux.
Retrograde flow of 1.0 seconds in common femoral,
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deep calf veins, and the superficial veins were used.14 Dis-
tribution and extent of thrombosis was evaluated in the
supine position. It was graded as acute, acute on chronic, or
chronic. Acute thrombosis was diagnosed based on the
following DU scan criteria:13 lack of compressibility, visual-
ization of intraluminal thrombus, vein dilatation, and filling
defects on color. The echotexture of the thrombus was ho-
mogenous and the wall-thrombus interface was smooth.
Evidence of chronic thrombosis was defined as echogenic
material in the lumen, heterogeneous thrombus echotex-
ture, intraluminal webs, wall thickening, and normal or
reduced luminal diameter. Presence of channels within the
thrombus and reflux, with or without enlarged collaterals,
were also indicative of chronic thrombosis. Acute on
chronic thrombosis (recurrent thrombosis) was identified
when a thrombus was found in a new vein segment that was
not affected on previous thrombotic event. Thrombosis in
a previously affected venous segment was detected by the
presence of both echogenic and echolucent material that
had a heterogeneous echotexture with dilatation of the vein
and lack of compressibility.13
Proximal DVT was defined as complete or partial
thrombosis of the popliteal, femoral, deep femoral, com-
mon femoral, iliac veins, and inferior vena cava. Based on
the plan of treatment with thrombolysis, proximal DVT
was further subclassified as follows: femoropopliteal DVT
which included the popliteal, femoral, and/or deep femoral
vein. Iliofemoral DVT was defined as thrombosis of any
part of the iliac and/or the common femoral vein, with or
without associated femoropopliteal DVT. Calf DVT was
defined as thrombosis in any of the following veins: anterior
and posterior tibial, peroneal, gastrocnemial, and soleal
veins. Anatomic location of the thrombus was categorized
using the venous segmental disease score.15
Patients with DVT were subsequently evaluated for
potential thrombolysis. Standardized criteria for indica-
tions (Table I) and contraindications (Table II) were used
to evaluate each patient.16 These data were entered pro-
spectively into a customized Microsoft Access Database.
Statistical analysis. Data were analyzed using the
SPSS (v 16, Chicago, Ill). Descriptive statistics were used
for the patients’ demographics. Differences in proportions
were compared with the 2 test. When the expected value
was 5 or less in any of the cells, the Fisher exact test was
Table I. Indications for pharmacologic catheter-directed t
Indication* Acceptable bleeding risk
Phlegmasia cerulea dolens Low-Moderate
Acute/subacute IVC thrombosis Low-Moderate
Acute iliofemoral DVT Low
Acute femoropopliteal DVT Low
Subacute/chronic iliofemoral DVT Low
†
DVT, Deep vein thrombosis; IVC, inferior vena cava; PE, pulmonary embo
*The suggested threshold for these indications is 95%.
†When thrombolytic therapy is being used.used.RESULTS
Of the 576 evaluated patients, 281 (49%) were male
and 295 (51%) were female with a mean age of 58 years,
ranging from 10 to 99. DVT was detected in 112 patients
(19.4%), 60 were male and 52 were female with a mean age
of 62.5 years (range, 17-99). Segmental distribution, loca-
tion, and age of thrombus are presented in Tables III and
IV. Proximal DVT was found in 81 patients (72%, 81/
112), while isolated calf DVT was found in 31 patients
(28%, 31/112). The anatomic distribution of proximal
DVT included the femoral-popliteal segments in 61 pa-
tients (54%, 61/112) and extension at least to the iliofem-
oral segments in 20 patients (18%, 20/112). Of patients
bolysis16
ife expectancy Primary goals
Any Limb salvage Survival
Any PE prevention Preserve organs Symptom relief
Long Prevent PTS
Long Prevent PTS
Long Alleviate PTS Prevent PTS
TS, post-thrombotic syndrome.
Table II. Contraindications to pharmacologic
catheter-directed thrombolysis16
Absolute contraindications
Active internal bleeding or disseminated intravascular
coagulation.
Recent cerebrovascular event (including transient ischemic
attacks), neurosurgery (intracranial, spinal), or intracranial
trauma (3 months).
Absolute contraindication to anticoagulation.
Strong relative contraindications
Recent cardiopulmonary resuscitation, major surgery, obstetrical
delivery, organ biopsy, or major trauma (10 days), recent eye
surgery (3 months).
Intracranial tumor, other intracranial lesion, or seizure disorder.
Uncontrolled hypertension: systolic 180 mm Hg, diastolic
110 mm Hg.
Recent major gastrointestinal bleeding (3 months).
Serious allergic or other reaction to thrombolytic agent,
anticoagulant, or contrast media (not controlled by steroid/
antihistamine pretreatment).
Severe thrombocytopenia.
Known right-to-left cardiac or pulmonary shunt or left heart
thrombus.
Massive PE with hemodynamic compromise.
Suspicion for infected venous thrombus.
Other relative contraindications







lism; Pwith proximal disease, acute thrombosis was found in 46
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chronic DVT (Fig).
In patients with femoral-popliteal DVT, 32 (52%, 32/
61) were acute, 13 were acute on chronic, and 11 were
chronic. Of acute DVT patients, 19 involved multiple
segments, whereas 13 were isolated to a single segment. In
patients with iliofemoral DVT, 14 patients (70%, 14/20)
were acute, and 6 (30%, 6/20) were chronic. Three pa-
tients had thrombus extending into the inferior vena cava
(Table III). In patients with isolated calf DVT, 26 patients
(84%, 26/31) were acute (Table IV). Of patients with
proximal DVT, 26 had contraindications to thrombolysis
(5 patients had absolute, and the remaining had relative
contraindications). When evaluating the 14 patients with
acute iliofemoral DVT, 10 patients were excluded based on
standard contraindications (Table V), leaving 4 eligible
candidates for thrombolysis (Fig). In patients with acute
femoral-popliteal DVT, 24 were excluded from treatment.
Eight patients had isolated popliteal vein thrombosis and
16 were excluded based on standard contraindications (Ta-
ble V). This left 8 remaining eligible candidates for throm-
bolysis (Fig).
In total, 12 patients were selected as potential candi-
Table III. Thrombus location as determined by initial
ultrasonography
Thrombus location No. of extremities/no. of patients
IVC 3 (3)
Common iliac 15 (14)
External iliac 16 (15)
Common femoral 56 (48)





IVC, Inferior vena cava.
Many patients had multiple sites involved.
Table IV. Location and age of thrombus categorized by
patient
Right Left Bilateral
n % n % n %
Proximal
Acute 21 19 32 29 7 6
Chronic 11 10 14 13 3 3
Acute and chronic 7 6 8 7 2 2
Total (n  81) 39 35 54 48 12 11
Calf (isolated)
Acute 15 13 16 14 5 4
Chronic 3 3 2 2 1 1
Acute and chronic 1 1 1 1 1 1
Total (n  31) 19 17 19 19 7 6
Bilateral cases do not represent additional patients.
Patients with proximal DVT may also have calf thrombosis.dates for treatment. This equates to a prevalence of 2%(12/576) in the population studied, 11% (12/112) of
patients with DVT, 26% (12/46) of patients presenting
with acute proximal DVT, and 20% (4/20) of patients with
iliofemoral DVT.
DISCUSSION
DVT of the lower extremity is a common disease that
can result in death from pulmonary embolism or significant
morbidity from chronic venous insufficiency. The reported
incidence of DVT in the lower extremity is estimated at 1.0
to 1.6 events per 1000 per year.17 Approximately 50% of
patients presenting with symptomatic DVT in the lower
extremity will have involvement of the proximal veins,18
and about 30% will develop long-term complications and
sequelae of the post-thrombotic syndrome.19 Until re-
cently, conventional treatment has been limited to the use
of anticoagulation therapy and compression stockings
Fig. Incidence of deep venous thrombosis (DVT) and potential
candidates for thrombolysis. * Thirteen patients presented with
acute/chronic DVT. † Eight patients with proximal DVT limited
to popliteal vein.
Table V. Patients who were contraindicated to
pharmacomechanical thrombolysis
Absolute contraindications Patients (n  5)
Recent cerebrovascular event 2
Neurosurgery (intracranial, spinal) 4
Intracranial trauma 3
Strong relative contraindications Patients (n  20)
Major gastrointestinal bleeding (3 months) 3
Major surgery (10 days) 9
Major trauma (10 days) 3
Intracranial tumor 7
Short life expectancy 12
Other relative contraindications Patients (n  1)
Pregnancy or lactation 1
Several patients presented with more than one contraindication.alone with disregard to the subset of patients at a higher risk
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ever, suggests that treatment strategies aimed at early
thrombus removal may improve clinical outcomes by elim-
inating venous obstruction, preserving valve competence,
and decreasing thrombus recurrence rates.6-9
The National Venous Registry20 demonstrated favor-
able outcomes in treatment of acute iliofemoral DVT with
catheter-directed thrombolysis. These outcomes were
maintained at 1-year follow-up. After the Registry data,
there have been several reports showing that local delivery
of thrombolytics combined with mechanical thrombolysis
provides good technical results with lower use of thrombo-
lytics and lower complication rates.20-23 Two randomized
trials6,7 subsequently looked at venous patency and reflux
after thrombolysis and demonstrated that successful throm-
bolysis results in improved venous function. If thrombolysis
improves venous function with lower incidence of reflux
and obstruction, the expectation would be improved clin-
ical outcome and better quality of life. Comerota et al9
reported that patients who underwent thrombolysis had
better overall physical functioning, less stigma, less health
distress, and fewer post-thrombotic symptoms when com-
pared with those treated with anticoagulation. Quality-of-
life results were directly related to the initial success of
thrombolysis.
To date, there is no large randomized prospective study
available to support the use of these techniques. Recently,
the 8th American College of Chest Physicians (ACCP)
guidelines24 included a level 2C recommendation, the use
of CDT in combination with PhMT in extensive acute
proximal DVT to reduce symptoms and post-thrombotic
morbidity. Venous thrombectomy has also been used for
treating acute proximal thrombosis with good long-term
outcomes which were better when compared to anticoag-
ulation alone.10,11 The National Institutes of Health
(NIH) has recently funded the Acute Venous Thrombosis:
Thrombus Removal with Adjunctive Catheter-Directed
Thrombolysis (ATTRACT) study, a multicenter random-
ized trial which will determine if PhMT can prevent post-
thrombotic syndrome. Another ongoing study in Nor-
way, the Catheter-directed Venous Thrombolysis (CaVenT)
trial,25 has already randomized 86 patients. It is planned to
enroll 200 patients to investigate the role of adjunctive
CDT by evaluating its clinical efficacy and safety compared
to conventional treatment alone. The number of patients
with DVT that would benefit from thrombolysis is not
known. Our study was designed to determine the number
of potential candidates for treatment using specific guide-
lines. It is important to mention that these guidelines were
taken from a consensus statement and are not strictly
evidenced-based. In addition, we evaluated the reasons for
which patients were not candidates and determined the
prevalence of the different contraindications.
The overall incidence of thrombosis in our study was
19.4% (112/576). However, 26 patients had chronic
thrombosis alone, and therefore the incidence of acute
DVT was 14.8% (85/576). The reported incidence of
patients examined in the vascular laboratory for acute DVTis 12% to 25%.26 Candidates for thrombolysis will vary
depending on the indications and contraindications that are
used. Limiting thrombolysis to the iliofemoral veins, 4 of
the 72 patients (5.6%) with acute thrombosis were candi-
dates using standard contraindications (Table II). How-
ever, of patients with acute iliofemoral DVT (n  14)
almost 1 in 3 would be a candidate (28.6%).
Of patients with proximal venous thrombosis, there is
little dispute in offering treatment for symptomatic acute
iliofemoral DVT. Controversy, however, exists on the ben-
efits of thrombolysis in femoropopliteal venous thrombo-
sis. With reported lower risks of bleeding complications,
PhMT has been offered in treating select patients. In the
current study, 40% of patients with proximal DVT (32/81)
were found to have acute thrombus localized to the femo-
ropopliteal segments. From these patients, 8 had isolated
popliteal vein thrombosis and 16 had contraindications to
treatment, leaving 8 eligible for thrombolysis. Providing
treatment to acute femoropopliteal DVT tripled our candi-
date population from 5.6% (4/72) in the iliofemoral veins
to 16.7% (12/72) (Fig).
A contraindication to thrombolytic therapy was present
in 10 of 14 patients (71.4%) with iliofemoral DVT and in
24 of 32 patients (75%) with femoropopliteal DVT. Of the
later, 13 patients had acute on chronic thrombosis and
potentially could also have been candidates for treatment.
However, patients with acute on chronic disease are usually
treated for iliofemoral thrombosis. Overall, of patients with
acute proximal DVT, 26.1% (12/46) were candidates for
treatment. This is a significantly higher incidence when
compared to the limited data in the literature. Casella et
al27 evaluated 260 patients with acute iliofemoral DVT and
selected 18 for thrombolysis (6.9%; P  .018 compared to
our incidence of 28.6% in the iliofemoral veins). Their data
were collected in a period of 5 years which means that less
than 4 patients per year were candidates for thrombolysis.
Markel et al28 retrospectively reviewed patients seen in the
vascular laboratory to rule out DVT. Of 833 patients
referred, there were 209 with a diagnosis of DVT (25%).
Using a nonstandardized list of contraindications, they
found that 7% of patients with DVT (15/209) would be
candidates for thrombolysis. This is similar to our findings
where 12 of 112 patients were candidates (10.7%; P .29).
However, this comparison cannot be accurate as they ex-
cluded only the calf veins and would treat patients with
isolated popliteal DVT. If the 5 patients with DVT in the
distal thigh and below were excluded, then their incidence
was 4.8% (P  .044).
The results of our study indicate that of patients evalu-
ated for DVT, only 0.7% (4/576) would be eligible for
thrombolysis considering the iliofemoral veins alone and
2.1% (12/576) when the femoropopliteal veins are in-
cluded. The corresponding numbers for those with acute
proximal DVT were 8.7% (4/46) and 26.1% (12/46). If
one were to plan a trial with 200 patients with iliofemoral
DVT, 28,800 would need to be evaluated. This number
would be 9600 when the femoropopliteal veins are in-
cluded. If the selection is done among patients with prox-
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and 633, respectively. These data were estimated from an
overall acute DVT incidence of 15%. If we were to use a
higher incidence, as reported in some series, the number of
patients required would be correspondingly smaller. In
contrast to other reports, our data distinguishes acute DVT
from acute on chronic and chronic DVT giving a clearer
account of the sample size needed. These figures should be
considered when evaluating the number of centers required
to recruit the necessary patient population for the trial.
CONCLUSIONS
This prospective study demonstrates that the number
of patients who are candidates for thrombolysis is low.
These data should be considered when recruiting centers to
participate in ongoing trials. Further improvement in me-
chanical devices to allow treatment with low bleeding com-
plications, and prospective studies with long-term data for
proximal DVT, could increase the patient population eligi-
ble for thrombolysis.
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